Account
Orders
Advanced search
Louise Reader
Read on Louise Reader App.
Tuberculosis (TB) is the leading cause of death by an infectious agent worldwide. The Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against TB and the most widely used vaccine in history. Since 1921, billions of people have been vaccinated with BCG, resulting in a remarkable decline in infant mortality. However, although BCG's efficacy to prevent TB meningitis and disseminated disease in children is well established, its efficacy to prevent infection, disease or reactivation in adolescents and adults is variable. Therefore, novel TB vaccines are urgently needed. Recent clinical trials have shown promising results, offering hope for the introduction of a new generation of vaccines to replace or boost BCG.
The book is structured into five sections, each providing sequential relevance to understanding the current landscape and future developments in TB vaccines. Section 1 introduces TB and the causative agent, Mycobacterium tuberculosis. Section 2 presents historical perspectives on BCG and TB vaccine candidates. Section 3 focuses on pre-clinical vaccines against TB. Section 4 examines vaccines against TB currently in clinical trials. Finally, section 5 discusses public health and societal challenges associated with the development of TB vaccines.
This book is an essential tool for students, clinicians, and scientists working in the fields of mycobacteriology, vaccine immunology, vaccine development, and TB vaccines, and it is anticipated to stimulate future research in TB vaccine development.
Les livres numériques peuvent être téléchargés depuis l'ebookstore Numilog ou directement depuis une tablette ou smartphone.
PDF : format reprenant la maquette originale du livre ; lecture recommandée sur ordinateur et tablette EPUB : format de texte repositionnable ; lecture sur tous supports (ordinateur, tablette, smartphone, liseuse)
DRM Adobe LCP
LCP DRM Adobe
This ebook is DRM protected.
LCP system provides a simplified access to ebooks: an activation key associated with your customer account allows you to open them immediately.
ebooks downloaded with LCP system can be read on:
Adobe DRM associates a file with a personal account (Adobe ID). Once your reading device is activated with your Adobe ID, your ebook can be opened with any compatible reading application.
ebooks downloaded with Adobe DRM can be read on:
mobile-and-tablet To check the compatibility with your devices,see help page
Paulo J. G. Bettencourt holds a BSc in Biotechnology from ISHT in Lisbon, Portugal, a Master's degree in Immunology and Immunogenetics from the University of Manchester, UK, and a PhD in Pharmacy from the University of Lisbon, Portugal. He completed seven years of post-doctoral research in Vaccinology at the renowned Jenner Institute at Oxford University, UK, where the ChAdOx1-S/nCoV-19 vaccine against COVID-19, and the R21 vaccine against malaria were developed.
Currently, he is an Assistant Professor, Principal Investigator, Director of the Research and Teaching Laboratories, and Coordinator of the MSc in Immunology and Vaccinology, at the new Faculty of Medicine at the Universidade Católica Portuguesa (UCP), which he co-founded. Additionally, he was appointed as the coordinator of the platform CatólicaMed at the Center for Interdisciplinary Research in Health, at UCP.
His postdoctoral research has led to the identification of three new candidate antigens for TB vaccines, currently in preclinical development. Prof. Bettencourt's current research is focused on three main areas: 1) the interaction between pathogens and the immune system focusing on the discovery of antigens using immunopeptidomics, 2) the translation of fundamental immunology into the design of mRNA vaccines against TB, malaria, and Staphylococcus aureus infections, and 3) the impact of Vaccination in Global Health.
Through the combination of immunology and vaccinology, Prof. Bettencourt aims to contribute to the development of innovative medical interventions with significant importance and impact for humanity.
Sign up to get our latest ebook recommendations and special offers